Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

  1. Emma C Tallantyre
  2. Martin J Scurr
  3. Nicola Vickaryous
  4. Aidan Richards
  5. Valerie Anderson
  6. David Baker
  7. Randy Chance
  8. Nikos Evangelou
  9. Katila George
  10. Gavin Giovannoni
  11. Katharine E Harding
  12. Aimee Hibbert
  13. Gillian Ingram
  14. Stephen Jolles
  15. Meleri Jones
  16. Angray S Kang
  17. Samantha Loveless
  18. Stuart J Moat
  19. Neil P Robertson
  20. Francesca Rios
  21. Klaus Schmierer
  22. Mark Willis
  23. Andrew Godkin
  24. Ruth Dobson

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.msard.2022.103937
  2. ScreenIT

    SciScore for 10.1101/2022.03.12.22272083: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: All participants provided written informed consent to take part in this study.
    IRB: This study has Research Ethics Committee approval (REC 19/WA/0058 (Wales REC 3 – covering samples processed in Cardiff), 05/WSE03/111 (South East Wales REC – covering samples processed in Cardiff) and 20/NE/0176 (Newcastle North Tyneside REC – covering QMUL samples).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Selection criteria were IgG negative anti-spike COVID-19 antibody status at week 4-8 post-COVID-19 vaccine 2, and willingness to provide a further blood sample 2-12 weeks following COVID-19 vaccine 3.
    anti-spike COVID-19
    suggested: (GeneTex Cat# GTX632604, RRID:AB_2864418)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.03.12.22272083v1 on medRxiv